283 related articles for article (PubMed ID: 34268903)
1. Structural and mechanistic insights into amyloid-β and α-synuclein fibril formation and polyphenol inhibitor efficacy in phospholipid bilayers.
Sanders HM; Jovcevski B; Marty MT; Pukala TL
FEBS J; 2022 Jan; 289(1):215-230. PubMed ID: 34268903
[TBL] [Abstract][Full Text] [Related]
2. NMR unveils an N-terminal interaction interface on acetylated-α-synuclein monomers for recruitment to fibrils.
Yang X; Wang B; Hoop CL; Williams JK; Baum J
Proc Natl Acad Sci U S A; 2021 May; 118(18):. PubMed ID: 33903234
[TBL] [Abstract][Full Text] [Related]
3. EGCG-mediated Protection of the Membrane Disruption and Cytotoxicity Caused by the 'Active Oligomer' of α-Synuclein.
Yang JE; Rhoo KY; Lee S; Lee JT; Park JH; Bhak G; Paik SR
Sci Rep; 2017 Dec; 7(1):17945. PubMed ID: 29263416
[TBL] [Abstract][Full Text] [Related]
4. The Aggregation Conditions Define Whether EGCG is an Inhibitor or Enhancer of
Sternke-Hoffmann R; Peduzzo A; Bolakhrif N; Haas R; Buell AK
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183378
[TBL] [Abstract][Full Text] [Related]
5. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers.
Ehrnhoefer DE; Bieschke J; Boeddrich A; Herbst M; Masino L; Lurz R; Engemann S; Pastore A; Wanker EE
Nat Struct Mol Biol; 2008 Jun; 15(6):558-66. PubMed ID: 18511942
[TBL] [Abstract][Full Text] [Related]
6. Lipids and EGCG Affect α-Synuclein Association and Disruption of Nanodiscs.
Sanders HM; Kostelic MM; Zak CK; Marty MT
Biochemistry; 2022 Jun; 61(11):1014-1021. PubMed ID: 35616927
[TBL] [Abstract][Full Text] [Related]
7. Polyphenol-solubility alters amyloid fibril formation of α-synuclein.
So M; Kimura Y; Yamaguchi K; Sugiki T; Fujiwara T; Aguirre C; Ikenaka K; Mochizuki H; Kawata Y; Goto Y
Protein Sci; 2021 Aug; 30(8):1701-1713. PubMed ID: 34046949
[TBL] [Abstract][Full Text] [Related]
8. Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative.
Gautam S; Karmakar S; Batra R; Sharma P; Pradhan P; Singh J; Kundu B; Chowdhury PK
Biochim Biophys Acta Proteins Proteom; 2017 May; 1865(5):589-603. PubMed ID: 28238838
[TBL] [Abstract][Full Text] [Related]
9. Polyphenol Honokiol and Flavone 2',3',4'-Trihydroxyflavone Differentially Interact with α-Synuclein at Distinct Phases of Aggregation.
Jovcevski B; Das S; Smid S; Pukala TL
ACS Chem Neurosci; 2020 Dec; 11(24):4469-4477. PubMed ID: 33185419
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the Role of Lipids in the Aggregation of Amyloidogenic Proteins.
Kurouski D
Acc Chem Res; 2023 Nov; 56(21):2898-2906. PubMed ID: 37824095
[TBL] [Abstract][Full Text] [Related]
11. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.
Gonçalves PB; Sodero ACR; Cordeiro Y
Biomolecules; 2021 May; 11(5):. PubMed ID: 34065606
[TBL] [Abstract][Full Text] [Related]
12. (-)-epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar state without redirecting its aggregation pathway.
Hudson SA; Ecroyd H; Dehle FC; Musgrave IF; Carver JA
J Mol Biol; 2009 Sep; 392(3):689-700. PubMed ID: 19616561
[TBL] [Abstract][Full Text] [Related]
13. Membrane lipid co-aggregation with α-synuclein fibrils.
Hellstrand E; Nowacka A; Topgaard D; Linse S; Sparr E
PLoS One; 2013; 8(10):e77235. PubMed ID: 24146972
[TBL] [Abstract][Full Text] [Related]
14. Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
Palazzi L; Fongaro B; Leri M; Acquasaliente L; Stefani M; Bucciantini M; Polverino de Laureto P
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199427
[TBL] [Abstract][Full Text] [Related]
15. How oxidized EGCG remodels α-synuclein fibrils into non-toxic aggregates: insights from computational simulations.
Gonçalves PB; Palhano FL; Cordeiro Y; Sodero ACR
Phys Chem Chem Phys; 2023 Jul; 25(28):19182-19194. PubMed ID: 37431676
[TBL] [Abstract][Full Text] [Related]
16. The Environment Is a Key Factor in Determining the Anti-Amyloid Efficacy of EGCG.
Sneideris T; Sakalauskas A; Sternke-Hoffmann R; Peduzzo A; Ziaunys M; Buell AK; Smirnovas V
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31835741
[TBL] [Abstract][Full Text] [Related]
17. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity.
Bieschke J; Russ J; Friedrich RP; Ehrnhoefer DE; Wobst H; Neugebauer K; Wanker EE
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7710-5. PubMed ID: 20385841
[TBL] [Abstract][Full Text] [Related]
18. Lipid membranes catalyse the fibril formation of the amyloid-β (1-42) peptide through lipid-fibril interactions that reinforce secondary pathways.
Lindberg DJ; Wesén E; Björkeroth J; Rocha S; Esbjörner EK
Biochim Biophys Acta Biomembr; 2017 Oct; 1859(10):1921-1929. PubMed ID: 28564579
[TBL] [Abstract][Full Text] [Related]
19. How epigallocatechin gallate binds and assembles oligomeric forms of human alpha-synuclein.
Andersen CB; Yoshimura Y; Nielsen J; Otzen DE; Mulder FAA
J Biol Chem; 2021; 296():100788. PubMed ID: 34019875
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
